Arterio-Venous Fistula Audit. Successful Utilisation Rates of Arterio-Venous Fistulae for Haemodialysis at University Hospital Limerick

Sponsor
University Hospital of Limerick (Other)
Overall Status
Completed
CT.gov ID
NCT05801549
Collaborator
(none)
70
1
3.9
17.9

Study Details

Study Description

Brief Summary

We wish to examine Arterio-Venous Fistula (AVF) and Arterio-Venous Graft (AVG) utilisation rates for Haemodialysis at University Hospital Limerick. We want to determine out of the AVF's that are surgically created, how many go on to be used as anticipated for haemodialysis treatments successfully.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    There are over 2 million end-stage renal disease (ESRD) patients who require renal replacement therapy worldwide, and this is estimated to rise to over 5 million by 2030 (Liyanage et al. 2015).

    Haemodialysis, used by the majority of ESRD patients, requires vascular access, where blood can be taken out of the body (via cannulation) and pumped through an external dialysis machine, which filters the blood of waste and excess fluid before being returned.

    Arterio-venous fistula creation is the preferred vascular access for haemodialysis, but has a large failure rate in the maturation period (Colley et al. 2022). Failure is usually attributed to insufficient dilation of the vessel and/or stenosis, which results in inadequate blood flow rates for the purpose of haemodialysis (Dixon, 2006).

    The purpose of this audit is to examine over a three year period how many of the individuals who had an AVF created are utilising it successfully for the purpose of haemodialysis as planned.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    70 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Arterio-Venous Fistula Audit. Successful Utilisation Rates of Arterio-Venous Fistulae for Haemodialysis at University Hospital Limerick
    Actual Study Start Date :
    Sep 13, 2022
    Actual Primary Completion Date :
    Dec 9, 2022
    Actual Study Completion Date :
    Jan 10, 2023

    Outcome Measures

    Primary Outcome Measures

    1. Number of AVF's created [3 years]

      We will determine how many were created surgically during the time frame.

    Secondary Outcome Measures

    1. AVF's in use for the purpose of Haemodialysis [3 years]

      We will dtermine how many are in use for haemodialysis as planned.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients who had an AVF or AVG surgically created over the last three years at UHL who are undergoing haemodialysis treatments are suitable for inclusion.

    • Dates for audit purposes are 1st April 2019 to 1st April 2022.

    Exclusion Criteria:
    • Patients outside of these set dates will be excluded.

    • Patients who are not currently undergoing haemodialysis treatments are excluded.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospital Limerick Limerick Ireland

    Sponsors and Collaborators

    • University Hospital of Limerick

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Fiona Leahy, CNM II Research, University Hospital of Limerick
    ClinicalTrials.gov Identifier:
    NCT05801549
    Other Study ID Numbers:
    • DVS007
    First Posted:
    Apr 6, 2023
    Last Update Posted:
    Apr 6, 2023
    Last Verified:
    Apr 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 6, 2023